EA PHARMA CO., LTD.
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- Subsidiary
- Established
- 2016-04-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.eapharma.co.jp
Clinical Trials
74
Active:2
Completed:54
Trial Phases
5 Phases
Early Phase 1:1
Phase 1:27
Phase 2:9
+2 more phases
Drug Approvals
3
NMPA:3
Drug Approvals
Enteral Nutritional Powder(AA)
- Product Name
- 肠内营养粉剂(AA)
- Approval Number
- 国药准字HJ20160479
- Approval Date
- Jun 9, 2022
NMPA
Enteral Nutritional Powder(AA)
- Product Name
- 肠内营养粉剂(AA)
- Approval Number
- 国药准字HJ20160478
- Approval Date
- Jun 9, 2022
NMPA
Enteral Nutritional Powder(AA)
- Product Name
- 肠内营养粉剂(AA)
- Approval Number
- 国药准字J20150122
- Approval Date
- Jan 28, 2019
NMPA
Clinical Trials
Distribution across different clinical trial phases (67 trials with phase data)• Click on a phase to view related trials
Phase 1
27 (40.3%)Phase 3
16 (23.9%)Not Applicable
12 (17.9%)Phase 2
9 (13.4%)phase_1_2
2 (3.0%)Early Phase 1
1 (1.5%)A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Bioavailability, and Food-effects of EA1080 in Healthy Caucasian and Japanese Male Participants
- First Posted Date
- 2020-01-13
- Last Posted Date
- 2023-12-26
- Lead Sponsor
- EA Pharma Co., Ltd.
- Target Recruit Count
- 184
- Registration Number
- NCT04223960
- Locations
- 🇬🇧
Richmond Pharmacology Ltd, London, United Kingdom
A Single Intravenous Dose of E3112 in Japanese Healthy Adult Male Participants
- First Posted Date
- 2019-04-22
- Last Posted Date
- 2021-03-15
- Lead Sponsor
- EA Pharma Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT03922633
- Locations
- 🇯🇵
EA Pharma Trial Site, Higashi, Fukuoka, Japan
A Study of E6011 in Participants With Active Crohn's Disease
- First Posted Date
- 2018-11-07
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- EA Pharma Co., Ltd.
- Target Recruit Count
- 25
- Registration Number
- NCT03733314
- Locations
- 🇨🇿
49, CCR Ostrava, s.r.o, Ostrava, Czechia
🇭🇺15, University of Debrecen Clinical Centre, Debrecen, Hungary
🇭🇺19, Semmelweis university, Győr, Hungary
A Study to Evaluate the Safety and Efficacy of AJM300 in Participants With Active Ulcerative Colitis
- First Posted Date
- 2018-05-22
- Last Posted Date
- 2023-07-21
- Lead Sponsor
- EA Pharma Co., Ltd.
- Target Recruit Count
- 198
- Registration Number
- NCT03531892
- Locations
- 🇯🇵
AJM300/CT3 trial site 41, Nagoya, Aichi, Japan
🇯🇵AJM300/CT3 trial site 57, Nagoya, Aichi, Japan
🇯🇵AJM300/CT3 trial site 63, Nagoya, Aichi, Japan
A Study to Determine the Absorption, Metabolism, and Excretion of [14C]-E6007 After a Single Oral Administration in Healthy Male Participants
Phase 1
Completed
- Conditions
- Healthy Male Participants
- Interventions
- Drug: [14C]-E6007
- First Posted Date
- 2018-02-23
- Last Posted Date
- 2018-08-29
- Lead Sponsor
- EA Pharma Co., Ltd.
- Target Recruit Count
- 6
- Registration Number
- NCT03444818
- Locations
- 🇬🇧
Covance Clinical Research Unit (CRU) Ltd., Leeds, West Yorkshire, United Kingdom
- Prev
- 1
- 2
- 3
- Next
News
No news found